NMD Pharma ApS has discovered chloride channel protein 1 (CLCN1; ClC-1) channel blockers reported to be useful for the treatment of myasthenia gravis, Lambert-Eaton syndrome, critical illness myopathy, amyotrophic lateral sclerosis, spinal muscular atrophy, Guillain-Barré syndrome, post-poliomyelitic and chronic fatigue syndrome, among others.
Caregen Co. Ltd. has identified peptides reported to be useful for the treatment of cartilage injury, fracture, intervertebral disc herniation, degenerative intervertebral disc disorder, osteoarthritis, osteomalacia and muscular injury.
Merck Sharp & Dohme LLC has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers from the University of Brescia have presented the discovery and preclinical characterization of novel fibroblast growth factor (FGF) trap small molecules, being developed for the treatment of multiple myeloma (MM).
Release Therapeutics SA has announced that it has secured CHF3.3 million (US$3.87 million) in seed funding. The proceeds will be used to finance primate studies of the company’s cell macroencapsulation technology for use in metachromatic leukodystrophy (MLD).
Researchers from Shanghai Jiao Tong University and affiliated organizations have presented data from a study that aimed to identify the prognostic markers related to abnormal methylation in ocular melanoma, including uveal melanoma (UM).
Meta Pharmaceuticals Inc. announced that the FDA has granted rare pediatric disease designation to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH), an autosomal recessive metabolic disorder in which oxalate is overproduced and deposited in the body.
Arcturus Therapeutics Holdings Inc. has announced its pandemic influenza vaccine is on track to enter a phase I clinical trial in Q4 of 2024. The vaccine, ARCT-2304, utilizes Arcturus’ STARR self-amplifying mRNA and LUNAR delivery platform technologies to deliver antigens designed to elicit a protective response against the H5N1 strain of avian influenza.
An abnormal epigenetic modification of RNA could be related to senescence and aging disorders, pointing towards the enzyme methyltransferase-like 1 (METTL1) as a potential therapeutic target.
Armed with $55 million in series A funds and a U.S. government contract, Cambridge, Mass.-based Red Queen Therapeutics Inc. launched operations this week, with plans to advance its novel stapled lipopeptide platform, which creates new antiviral therapies that do not rely on the immune system to work.
RSS
